back to conferences

15th International Conference on Parkinson’s and Alzheimer’s Diseases

date

March 9-14, 2021

location

Virtual
The 15th​ International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD/PD™ 2021, will build on the well-earned reputation of the groundbreaking series of Alzheimer’s and Parkinson’s Diseases Conferences, which attract international medical and scientific professionals worldwide.​​
In light of the continuing uncertainty about the evolution of the COVID-19 pandemic and its impact on travel restrictions and physical distancing requirements throughout 2021, the AD/PD™ Organizing Committee has decided to transform this COVID crisis into a new opportunity and will hold the AD/PD™ 2021 conference as a fully online, virtual experience.

Quanterix will be sponsoring this important event with a virtual booth and lobby video.

Poster presentations featuring research facilitated by Simoa technology:

P220 / #1487      J. Kaplow, et al
Theme A: ß-Amyloid Diseases / A4.c. Imaging, Biomarkers, Diagnostics: PET – amyloid     
PERFORMANCE OF CSF AD BIOMARKERS IN PREDICTING AMYLOID PET POSITIVITY IN EARLY AD: DATA FROM EISAI’S MISSIONAD PROGRAM

P232 / #566        D. Alcolea, et al
Theme A: β-Amyloid Diseases / A4.h. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers              
PLASMA BIOMARKERS IN THE AT(N) CATEGORIES FOR THE DETECTION OF ALZHEIMER’S DISEASE

P233 / #1264     E. Andersson, et al          
Theme A: β-Amyloid Diseases / A4.h. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers              
CEREBROSPINAL FLUID AΒ42 AND AΒ40 AND THEIR RELATION TO SOLUBLE AND INSOLUBLE AΒ IN THE BRAIN IN ALZHEIMER’S DISEASE

P245 / #1259      A. Moscoso, et al            
Theme A: β-Amyloid Diseases / A4.h. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers              
ASSOCIATION OF BLOOD PHOSPHORYLATED TAU181 AND NEUROFILAMENT LIGHT WITH PROGRESSIVE NEURODEGENERATION IN ALZHEIMER DISEASE

P254 / #1287      C. Rubel, et al    
Theme A: β-Amyloid Diseases / A4.h. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers              
CROSS-PLATFORM EVALUATION OF HIGHLY SENSITIVE IMMUNOASSAY TECHNOLOGIES FOR SERUM MEASURES OF PTAU181: PERFORMANCE IN ALZHEIMER’S DISEASE

P255 / #1284      J. Simrén, et al  
Theme A: β-Amyloid Diseases / A4.h. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers              
ALTERNATIVE PROTOCOLS TO SUPPORT BLOOD COLLECTION IN CHALLENGING PRE-ANALYTICAL CONDITIONS

P302 / #1436     C. Johansson, et al          
Theme A: β-Amyloid Diseases / A6.a. Cell, Molecular and Systems Biology: APP, APLP, Abeta DIFFERENTIAL PLASMA BIOMARKER PROFILE IN FAMILIAL ALZHEIMER DISEASE

P384 / #934       K. Foster, et al   
Theme B: Taupathies / B2.b. Therapeutic Targets, Mechanisms for Treatment: Immunotherapy  
EVALUATION OF PNT001, A MONOCLONAL ANTIBODY DIRECTED TOWARD CIS-PT231 TAU, IN HUMAN TISSUE AND THE TG4510 TAU TRANSGENIC MOUSE

P391 / #659        T. Miyasaka, et al             
Theme B: Taupathies / B2.m. Therapeutic Targets, Mechanisms for Treatment: Other      
THE EXPRESSION OF MICROTUBULE ASSOCIATED PROTEIN TAU IN MICE PODOCYTE.

P538 / #1227     S. Canaslan, et al              
Theme C: α-Synucleinopathies / C4.f. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers             
DETECTION OF DIAGNOSTIC RELEVANT BIOMARKER PROTEINS IN PLASMA AND CSF OF ALPHA SYNUCLEINOPATHIES BY SINGLE MOLECULE ARRAY (SIMOA)

P369 / #683   N. Zhu, et al       
Theme B: Taupathies / B1.j. Disease Mechanisms, Pathophysiology: Astroglia 
PLASMA GLIAL FIBRILLARY ACIDIC PROTEIN AND NEUROFILAMENT, AND THEIR COMBINATION AS BIOMARKERS IN FRONTOTEMPORAL DEMENTIA

P240 / #893    M. Grothe, et al              
Theme A: β-Amyloid Diseases / A4.h. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers           
NEUROPATHOLOGIC CORRELATES OF ELECSYS-DERIVED CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER’S DISEASE IN COMPARISON TO A NOVEL PLASMA-BASED P-TAU181 BIOMARKER

P482 / #1461 A. Pilotto, et al  
Theme C: α-Synucleinopathies / C1.p. Disease Mechanisms, Pathophysiology: Modeling of disease progression  
PLASMA INFLAMMATORY AND NEURODEGENERATION MARKERS AND DISEASE PROGRESSION IN LEWY BODIES DISORDERS

P540 / #417   K. Fraser, et al   
Theme C: α-Synucleinopathies / C4.f. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers           
EVALUATING SERUM NEUROFILAMENT LIGHT AS A MEASURE OF TREATMENT RESPONSE IN STANDARD SIZED PH2 PARKINSON’S DISEASE TRIALS

Poster presentation featuring research performed using the Uman NF-Light™ Assay:

P545 / #175   E. Papuć, et al   
Theme C: α-Synucleinopathies / C4.f. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers           
INCREASED CSF NFL IN NON-DEMENTED PARKINSON’S DISEASE PATIENTS REFLECTS EARLY WHITE MATTER DAMAGE

View Full Abstract Book